Trials / Active Not Recruiting
Active Not RecruitingNCT06622226
A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) in Japan
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
ONO-7018 is a selective inhibitor of mucosa associated lymphoid tissue protein 1 (MALT1) and is expected to exhibit antitumor activity in NHL. This study is Phase1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (biomarkers) and efficacy of ONO-7018 in patients with relapsed or refractory NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-7018 | ONO-7018 tablet(s) are administered orally. |
Timeline
- Start date
- 2024-11-27
- Primary completion
- 2027-07-31
- Completion
- 2029-12-31
- First posted
- 2024-10-02
- Last updated
- 2025-02-18
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06622226. Inclusion in this directory is not an endorsement.